Medications for Percutaneous Coronary Intervention (PCI)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Percutaneous Coronary Intervention (PCI).
Found 4 Approved Drugs for Percutaneous Coronary Intervention (PCI)
Bivalirudin
Generic Name
Bivalirudin
Bivalirudin
Generic Name
Bivalirudin
Form: Injection
Method of administration: Intravenous, Intracavernous
FDA approval date: October 28, 2016
Classification: Direct Thrombin Inhibitor
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). ( 1 )
Eptifibatide
Generic Name
Eptifibatide
Eptifibatide
Generic Name
Eptifibatide
Form: Injection
Method of administration: Intravenous
FDA approval date: December 08, 2015
Classification: Platelet Aggregation Inhibitor
Eptifibatide Injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI).
Kengreal
Generic Name
Cangrelor
Kengreal
Generic Name
Cangrelor
Form: Injection
Method of administration: Intravenous
FDA approval date: July 08, 2015
Classification: P2Y12 Platelet Inhibitor
Cangrelor for injection is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies (1.
Argatroban
Generic Name
Argatroban
Argatroban
Generic Name
Argatroban
Form: Injection, Solution
Method of administration: Intravenous
FDA approval date: January 05, 2012
Classification: Direct Thrombin Inhibitor
Argatroban in sodium chloride injection is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT).
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances